Background and Purpose A non‐psychoactive phytocannabinoid, cannabidiol (CBD), shows
promising results as an effective potential antiepileptic drug in some forms of refractory …

The present study reports the behavioral, electrophysiological, and neuropathological
effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa, in the …

Plant-derived cannabinoids (phytocannabinoids) are compounds with emerging therapeutic
potential. Early studies suggested that cannabidiol (CBD) has anticonvulsant properties in …

Epilepsy is a neurological disorder characterized by the presence of seizures and
neuropsychiatric comorbidities. Despite the number of antiepileptic drugs, one-third of …

Cannabis sativa has been associated with contradictory effects upon seizure states despite
its medicinal use by numerous people with epilepsy. We have recently shown that the …

Anticonvulsant effects of cannabidiol (CBD), a nonpsychoactive cannabinoid, have not been
investigated in the juvenile brain. We hypothesized that CBD would attenuate epileptiform …

Presently there is no drug therapy for curing epilepsy. Despite many advancements in
epilepsy research, nearly 30% of people with epilepsy remain refractory to current …

Despite the introduction of new antiepileptic drugs (AEDs), the quality of life and therapeutic
response for patients with epilepsy remains still poor. Unfortunately, besides several …

Background and Purpose Phytocannabinoids in C annabis sativa have diverse
pharmacological targets extending beyond cannabinoid receptors and several exert notable …

Microglia, the dynamic innate immune cells of the central nervous system, become activated
in epilepsy. The process of microglial activation in epilepsy results in the creation of an …